In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Endo acquires Canadian spec pharma Paladin for $Cdn1.5bn

Executive Summary

Endo Health Solutions Inc. acquired publicly traded Canadian spec pharma Paladin Labs Inc. for $Cdn1.5bn ($1.5bn). New Endo, a holding company based in Ireland, was formed, and each current Endo share is equivalent to one New Endo share. New Endo will own the combined Endo/Paladin and trade on Nasdaq, with Endo stockholders controlling 77.5% of the combined company, and Paladin the rest (because of this structure, the transaction isn’t expected to be taxable to Endo’s US shareholders, but will be taxable to Paladin’s in Canada). Paladin retains its name, current management, and Montreal headquarters.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies